This webcast was originally recorded May 21, 2019. Follow this link for webcast with Hebrew Subtitles. Listen to the webcast - Hebrew subtitles Are you interested in optimizing your treatment? In [...]
The FDA granted the approval of Rozlytrek™ (entrectnib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), The FDA has also granted accelerated approval to Rozlytrek for the treatment of [...]
When to Consider Surgery This webcast will address the issues surrounding the decision to have an operation. Most GIST patients will see a surgeon at some point during their treatment. The decision to consider [...]
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry. This study highlights the very unique research role that defines The Life Raft Group.
In 2018, The Life Raft Group continued its dedication to patients with GIST, working diligently to enhance survival and quality of life through research, information, education, advocacy, and outreach & engagement. These efforts would [...]
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]
SPAEN (Sarcoma Patients EuroNet) Presents Webinar Webinar "Novel therapy options in GIST: What's on the horizon?" was presented by Dr. Jonathan Trent, Professor of Medicine, Associate Director, Clinical Research Director, Sarcoma Medical Research Program [...]
The Life Raft Group held a GIST Day of Learning (GDOL) in Portland, at Oregon Health & Science University (OHSU), on June 22nd, 2019. GDOLs are free, one-day programs that provide both education and [...]
Presentación del Dr. Chris Corless, profesor de patología en la Universidad de Oregón. Habla desde experiencia como patólogo trabajando con los tumores del estroma gastrointestinal (GIST). Nos actualiza sobre diagnóstico, mutaciones, riesgos de recurrencia, [...]
